Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-α

Journal of Clinical Gastroenterology

Volumn 29, Issue 2, 1999, Pages 207-209

  Yamaguchi, Kanae ^b   Omagari, Katsuhisa ^a   Kinoshita, Hideki ^b   Yoshioka, Sumako ^b   Furusu, Hisashi ^b   Takeshima, Fuminao ^b   Nanashima, Atsushi ^b   Yamaguchi, Hiroyuki ^b   Kohno, Shigeru ^b  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Hepatitic C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; ERADICATION THERAPY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0032801489     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199909000-00024     Document Type: Article

References (23)

1. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
2. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996;125:658-68.
3. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
4. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
5. International interferon-α hepatocellular carcinoma study group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective study. Lancet 1998;351:1535-9.
6. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
7. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998;129:94-9.
8. Miyajima I, Sata M, Kumashiro R, et al. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncol Rep 1998;5:201-4.
9. Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep 1998;5:205-8.
10. Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6:112-9.
11. Omagari K, Ikuno N, Imanishi T, et al. Interferon-alpha 2a treatment for chronic hepatitis C without cirrhosis and its effects on incidence of hepatocellular carcinoma. J Infect Chemother 1998;4:209-13.
12. Sato A, Kato Y, Nakata K, et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J Gastroenterol Hepatol 1996;11:944-8.
13. Tarao K, Takemiya S, Tamai S, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997;79:688-94.
14. Chang J, Yang S-H, Cho Y-G, Hwang SB, Hahn YS, Sung YC. Hepatitis C virus core from two different genotypes has an oncogenic potential but is not sufficient for transforming primary rat embryo fibroblasts in cooperation with the H-ras oncogene. J Virol 1998;72:3060-5.
15. Koretz RL. Interferon and hepatocellular carcinoma. Lancet 1996; 347:194.
16. Andreone P, Cursaro C, Gramenzi A, Trevisani F, Gasbarrini G, Bemardi M. Interferon and hepatocellular carcinoma. Lancet 1996; 347:195.
17. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
18. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
19. Lai C-L, Lau JYN, Wu P-C, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94.
20. Kuroki T, Nishiguchi S, Nakatani S. Reply: interferon and hepatocellular carcinoma. Lancet 1996;347:194-5.
21. Hirashima N, Mizokami M, Orito E, et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-α. J Gastroenterol Hepatol 1996;11:955-8.
22. Gil B, Qian C, Riezu-Boj JI, Civeira MP, Prieto J. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology 1993;18:1050-4.
23. Uchida T, Shimojima M, Gotoh K, Shikata T, Tanaka E, Kiyosawa K. "Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol Immunol 1994;38:281-5.